The Synovasure Alpha Defensin Lateral Flow Test is a standalone, rapid device for detecting alpha defensin in synovial fluid. The test received FDA authorization in 2019 as a CLIA moderately complex test.

Results in 10 minutes following performance of test.

Demonstrates a high sensitivity (94.3%) and specificity (94.5%). In addition, results proven in clinical studies to be unaffected by:

• Prior antibiotic administration^1,2,3

• Comorbidities related to inflammation^1,2,4

• Type and/or virulence of the organism^1,2,5

Only needs 15 microliters of synovial fluid to perform test.

No statistically significant difference in performance of Synovasure Alpha Defensin Lateral Flow Test and Synovasure Alpha Defensin ELISA laboratory test.

• Infection Diagnostics

• Revision Knee 

• Revision Hip

Sensitivity vs. standard of care criteria.¹

Specificity vs. standard of care criteria.¹

^{*Excluding samples with >20% blood}